glutathione and concussion A potential new treatment for brain injury Mark Gordon MD Traumatic Brain

Phase 3 TRIUMPH topline figures (often cited around the high-20% range at 6880 weeks) are company-reported and, at the time of writing, are not the peer-reviewed Phase 2 dataset cited above

Research involving BPC-157 has expanded significantly in studies related to tissue pathways, angiogenesis research, and controlled laboratory investigations involving peptide receptor activity

Peptides like BPC-157 and TB-500 are studied for supporting connective tissue repair, which is why they interest people with nagging tendon and ligament issues

Clinical trials involving approximately 900 participants across six studies demonstrated excellent safety and tolerability